Aditxt, Inc. (ADTX): debt financing — Aditxt raises $1M in senior notes, invests $925K in Evofem; CEO targets Evofem close by Sept 2025

Aditxt, Inc.

Issued $1M senior notes (10% interest, maturity Sept 30, 2025) at $800K purchase price (20% original issue discount).
Purchased $1.42M Evofem convertible note and warrant for $925K; convertible at $0.0154/share, warrant exercisable for 5 years.
Evofem reported ~$20M revenue in 2024; CEO says pending acquisition target close by end of September 2025, subject to shareholder approval.
Pearsanta near commercialization (end 2025/Q1 2026) for prostate cancer and endometriosis tests using mitochondrial DNA.
Adimune autoimmune therapeutic platform still early stage; described as 'sleeping giant'; retraining immune system approach.

item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Aditxt, Inc. incurred senior notes of $1,000,000 aggregate original principal amount with accredited investors at 10% per annum maturing September 30, 2025.

Instrument: senior notes
Principal: $1,000,000 aggregate original principal amount
Counterparty: accredited investors
Rate: 10% per annum
Maturity: September 30, 2025
Event: incurrence

Exact text from the filing

On June 26, 2025, Aditxt, Inc. (the “ Company ”) issued and sold senior notes (each, a “ Note ”) to accredited investors in the aggregate original principal amount of $1,000,000 for a purchase price of $800,000, reflecting an aggregate original issue discount of $200,000. The Notes bear interest at a rate of 10% per annum and have a maturity date of September 30, 2025 (the “ Maturity Date ”).

View on SEC.gov

103 debt financings filed in the last 30 days. Browse all debt financings →

Aditxt, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-060391

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.